Product Description
ACE-232 is a novel, orally active, and highly selective inhibitor of CYP11A1 developed to target both localized or metastatic hormone-sensitive or castration-resistant prostate cancer. It can effectively overcome acquired resistance to androgen receptor pathway inhibitors (ARPI, abiretarone or enzalutamide) due to AR-LBD mutations or amplification. Preclinical studies have shown that ACE-232 exhibits excellent in vitro and in vivo potency, and a favorable pharmacokinetic and safety profile, with best-in-class potential. Based on these promising results, Acerand Therapeutics will promptly launch a Phase 1 study in the U.S. to further evaluate the potential of ACE-232 as both a monotherapy and combination therapy. (Sourced from: https://www.acerand.com/nw_20250117.html)
Mechanisms of Action: CYP11A1 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Acerand Therapeutics (Hong Kong) Limited
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Adenocarcinoma|Prostate Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ACE-232-001 | P1 |
Not yet recruiting |
Prostate Cancer|Adenocarcinoma |
2028-03-01 |